Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.

Leukemia Research
Desheng XiaoYongguang Tao

Abstract

Myeloid sarcoma is a tumor mass that consists of myeloblasts or immature myeloid cells at an extramedullary site. Pathological diagnosis is very difficult based on morphology if systemic signs of disease are absent. The subtype of myeloid sarcoma is also minimally identifiable in the histological picture. We investigated 18 paraffin-embedded myeloid sarcoma samples, and our immunohistochemical data confirmed the relevance of some key markers for the diagnosis and subclassification of myeloid sarcoma. CD34 was found as a marker in 67% of the myeloid sarcoma cases, and CD34 was positive in all immature types of myeloid sarcoma. CD68 was found in 83% of the myeloid sarcoma cases, but CD68 was most identified in the differentiated type of myeloid sarcoma. Myeloperoxidase (MPO) was positive in all myeloid sarcomas. Notably, the reactivity of MPO in the blastic subtype was much lower in myeloid sarcomas. CD117 reactivity was found in 67% of myeloid sarcomas. Ten-eleven translocation 2 (TET2) protein exhibited significant negative reactivity in 88% of the cases, and 5-methylcytosine (5-hmC) was significantly positive in the nucleus in 100% of the cases. Our findings indicated that an immunohistochemical panel that included MPO, CD68 a...Continue Reading

References

Feb 3, 2000·Journal of Clinical Pathology·E AstallR Marcus
Jun 13, 2003·Leukemia Research·Hans G Drexler, Roderick A F MacLeod
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer L JohnsonKenneth Zuckerman
May 6, 2008·Leukemia Research·Henning Sebastian SchäferMichael Lübbert
Jul 29, 2009·Blood·Michael StefanidakisErkki Koivunen
Aug 4, 2009·Stem Cells·Sichuan XiKathrin Muegge
Aug 19, 2009·American Journal of Clinical Pathology·Cristina CampidelliStefano A Pileri
Sep 11, 2009·The New England Journal of Medicine·Ayalew TefferiRoss Levine
Mar 24, 2011·Proceedings of the National Academy of Sciences of the United States of America·Yongguang TaoKathrin Muegge
May 15, 2012·Leukemia Research·Andrew Riddle, Brian Olsen
Jun 27, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anis ToumehIman Mohamed
Jan 3, 2013·International Journal of Cancer. Journal International Du Cancer·Maro OhanianZeev Estrov
Feb 26, 2013·Cell·Cornelia G SpruijtMichiel Vermeulen
Mar 19, 2013·Current Opinion in Cell Biology·Li Shen, Yi Zhang

❮ Previous
Next ❯

Citations

Dec 15, 2017·Journal of Cancer Research and Therapeutics·Qiuyan HeDesheng Xiao
Aug 24, 2019·International Journal of Laboratory Hematology·Ping ZhangYong-Min Tang
Oct 2, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zuli WangYongguang Tao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Related Papers

Arkhiv patologii
E E Leenman, Iu A Krivolapov
American Journal of Clinical Pathology
Jose R ValbuenaL Jeffrey Medeiros
© 2021 Meta ULC. All rights reserved